10-Q: Entera Bio Advances Programs, Faces Funding Gap

Entera Bio Ltd. reported increased operating losses but secured significant financing and advanced its lead osteoporosis and obesity drug candidates, though substantial doubt remains about its ability to fund future operations.

Summary

• Reported a net loss of $5.2 million for the six months ended June 30, 2025, an increase from $4.2 million in the same period of 2024.
• Operating expenses increased by 24% to $5.2 million for the six months ended June 30, 2025, primarily driven by a 45% increase in research and development expenses.
• Cash and cash equivalents, along with restricted cash, totaled $18.9 million as of June 30, 2025, including $8.0 million specifically designated for the OPKO collaboration.
• The FDA agreed on a single Phase 3 study design for EB613 (oral PTH(1-34)) for postmenopausal osteoporosis, with Total Hip BMD as the primary endpoint, allowing advancement without waiting for SABRE qualification.
• Entered into a collaboration and license agreement with OPKO Biologics Ltd. on March 16, 2025, for the oral OXM (GLP-1/Glucagon) program for obesity, metabolic, and fibrotic disorders.
• Issued 3,685,226 ordinary shares to OPKO for $8.0 million as part of the collaboration agreement, with proceeds escrowed for development costs.
• Raised $6.0 million net proceeds from the issuance of 2,700,000 ordinary shares under the Leerink ATM Program in January 2025.
• Management believes existing cash resources are sufficient to support operations through the middle of the third quarter of 2026, but this excludes the capital required for the proposed Phase 3 program for EB613.
• Substantial doubt exists regarding the company's ability to continue as a going concern due to accumulated deficit and negative cash flows from operations.

Sentiment

Score: 4

Explanation: The sentiment is mixed, leaning slightly negative. While there are significant positive developments in clinical programs (FDA agreement for EB613 Phase 3, promising oral OXM data, OPKO collaboration, and successful capital raises), the explicit 'going concern' warning and the immediate need for substantial additional funding for the flagship EB613 Phase 3 program introduce considerable financial uncertainty and risk.

Positives

• FDA agreed to a single Phase 3 study design for EB613 in osteoporosis, using Total Hip BMD as the primary endpoint, which streamlines the regulatory pathway and allows the program to advance without waiting for the broader SABRE qualification.
• Secured a significant collaboration and license agreement with OPKO Biologics Ltd. for the oral OXM (GLP-1/Glucagon) program, leveraging the N-Tab technology for obesity and metabolic disorders.
• The OPKO collaboration included an $8.0 million equity investment by OPKO, providing dedicated funding for Entera's share of development costs for the oral OXM program.
• Successfully raised $6.0 million in net proceeds through the At-The-Market (ATM) program in January 2025, enhancing liquidity.
• Positive preclinical and Phase 1 data for oral OXM demonstrated significant systemic exposure, a favorable pharmacokinetic profile, and a statistically significant reduction in plasma glucose levels.
• The company's N-Tab technology continues to show promise in enabling oral delivery of peptides, with ongoing research and development for new generations of EB613 and other peptides.

Negatives

• Net loss increased to $5.2 million for the six months ended June 30, 2025, compared to $4.2 million for the same period in 2024, indicating a widening financial deficit.
• Operating losses increased to $5.2 million for the six months ended June 30, 2025, up from $4.2 million in the prior year period.
• The company has an accumulated deficit of $119.2 million as of June 30, 2025, and has incurred negative cash flows from operating activities since inception.
• Management has identified substantial doubt about the company's ability to continue as a going concern, primarily due to its history of losses and reliance on future financing.
• Existing cash resources are explicitly stated as insufficient to fund the proposed Phase 3 program for EB613 in osteoporosis, necessitating additional capital raises.
• Revenue for the six months ended June 30, 2025, was minimal at $42 thousand, and gross profit was zero, highlighting the lack of product sales and reliance on development-stage activities.

Risks

• Clinical development is a lengthy, expensive, and uncertain process with unpredictable outcomes, potentially leading to additional costs or inability to commercialize product candidates.
• Regulatory approval processes by the FDA and foreign authorities are lengthy, time-consuming, and inherently unpredictable, posing a risk to obtaining necessary approvals.
• Preclinical programs may experience delays or fail to advance to clinical trials, adversely affecting the ability to obtain regulatory approvals or commercialize programs.
• Positive results from preclinical studies and early-stage clinical trials may not be predictive of future results in later-stage trials.
• The scope, progress, and costs of developing product candidates like EB613 and EB612 may change based on regulatory requirements, collaboration agreements, competitive environment, and new data.
• The accuracy of estimates regarding expenses, capital requirements, sufficiency of cash resources, and the need for additional financing is uncertain.
• The company's ability to continue as a going concern is in substantial doubt without access to additional sources of liquidity.
• Failure to raise additional funds or consummate strategic partnerships could delay, limit, or reduce product development and other operations.
• Even if approved, product candidates may fail to achieve market acceptance by physicians, patients, and payors, limiting commercial success.
• Failure to obtain or maintain adequate coverage and reimbursement for approved product candidates could limit marketability and revenue generation.
• Inability to obtain and maintain robust patent protection for product candidates could allow competitors to develop similar products, adversely affecting commercialization.
• Reliance on third parties to conduct clinical trials and supply/produce product candidates introduces external dependencies and risks.
• The duration and intensity of the ongoing Israel-Hamas War and escalating conflicts in the Middle East could impact operations and workforce, despite currently immaterial effects.

Future Outlook

The company plans to initiate a Phase 3 registrational study for EB613 in osteoporosis, following FDA concurrence on the study design. It also intends to file an Investigational New Drug (IND) application with the FDA later this year for the oral OXM (GLP-1/Glucagon) program in collaboration with OPKO. Ongoing N-Tab technology research and development, including an additional Phase 1 PK study for a new generation of EB613 and SAD/MAD Phase 1 studies for oral OXM, are also planned. Management believes existing cash resources are sufficient to fund operations through mid-Q3 2026, but explicitly states that this does not include the capital required for the EB613 Phase 3 program, indicating a need for significant additional financing.

Management Comments

• Management continually evaluates various financing alternatives and strategic collaborations, as the Company will need to finance future research and clinical development with additional capital.
• Our ability to commence the Phase 3 program of EB613 in osteoporosis will require additional funding, which may not be available on reasonable terms, or at all. Any delay or our inability to secure such funding will delay or prevent the commencement of this study.
• Given our current plans, we believe that our existing cash resources will be sufficient to support the Company’s operations under its current plans through the middle of the third quarter of 2026.
• Currently, the Company’s activities in Israel remain largely unaffected by the ongoing Israel-Hamas War and related conflicts, and we do not expect any delays to any of our programs as a result of such conflicts.

Industry Context

Entera Bio operates in the highly competitive and capital-intensive biotechnology sector, specifically focusing on oral peptide delivery, a challenging but potentially transformative area. The development of oral forms of therapies like PTH(1-34) for osteoporosis and GLP-1/Glucagon agonists for obesity addresses significant unmet needs in chronic disease management, where current treatments often involve inconvenient injections. The company's N-Tab platform aims to overcome the technical hurdles of enzymatic degradation and poor absorption in the gastrointestinal tract. The collaboration with OPKO for an oral GLP-1/Glucagon agonist positions Entera in a rapidly growing market for obesity and metabolic disorders, competing with established injectable and emerging oral therapies.

Comparison to Industry Standards

• Oral OXM's high plasma concentrations with prolonged systemic exposure were consistent with the reported half-life for semaglutide (Rybelsus), the only approved oral GLP-1 analog, suggesting competitive pharmacokinetic potential for Entera's oral GLP-1/Glucagon program.

Related Party Transactions

• On March 16, 2025, the company entered into a collaboration and license agreement with OPKO and its wholly owned subsidiary, OPKO Biologics Ltd. In connection with this, the company issued and sold to OPKO 3,685,226 ordinary shares for $8.0 million. OPKO agreed to a 12-month lockup and a 24-month standstill provision, restricting further equity acquisition or certain other actions without consent.

Stakeholder Impact

• Shareholders face potential dilution from future capital raises and significant risk due to the 'going concern' warning, but also potential upside from successful clinical development and commercialization of pipeline assets.
• Employees, particularly those in Israel, are subject to potential impacts from the ongoing geopolitical conflicts, although the company currently reports immaterial effects on operations.
• Patients with osteoporosis, hypoparathyroidism, obesity, and metabolic disorders could benefit from novel oral peptide therapies if product candidates like EB613, EB612, and oral OXM achieve regulatory approval and commercialization.
• Collaborators like OPKO are directly impacted by the success and funding of the joint oral OXM program, sharing in both proceeds and development costs.

Next Steps

• Initiate a Phase 3 registrational study for EB613 in postmenopausal osteoporosis.
• File an Investigational New Drug (IND) application with the FDA for the oral OXM (GLP-1/Glucagon) program later this year.
• Complete an additional Phase 1 PK study related to the company's new generation of EB613.
• Complete SAD (Single Ascending Dose) and MAD (Multiple Ascending Dose) Phase 1 proposed studies of oral OXM (GLP-1/Glucagon tablet) in collaboration with OPKO.
• Continue to evaluate various financing alternatives and strategic collaborations to secure additional capital for future research and clinical development.

Key Dates

Keywords

Entera Bio, ENTX, Oral Peptide, N-Tab Technology, Osteoporosis, EB613, Hypoparathyroidism, Obesity, Metabolic Disorders, GLP-1, Glucagon, OXM, OPKO Biologics, FDA, Phase 3 Clinical Trial, Biotechnology, Drug Development, SEC Filing, 10-Q